In brief: Antipsychotic choice in early-onset schizophrenia
Antipsychotic choice in early-onset schizophrenia
Another study raises questions about the relative efficacy of first- and second-generation antipsychotics.
In the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study, investigators randomly assigned 119 patients, ages 8 to 19, diagnosed with early-onset schizophrenia or schizoaffective disorder to treatment with the first-generation drug molindone (Moban) or one of two second-generation drugs, olanzapine (Zyprexa) or risperidone (Risperdal). Some patients were just diagnosed or "first episode," while others had chronic illness. Medications were prescribed at moderate doses.